Zacks: Novogen Ltd. (NASDAQ:NVGN) Given Consensus Recommendation of “Strong Buy” by Analysts
Shares of Novogen Ltd. (NASDAQ:NVGN) have received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Zacks has also given Novogen an industry rank of 94 out of 265 based on the ratings given to its competitors.
Novogen (NASDAQ:NVGN) traded up 2.60% during mid-day trading on Tuesday, reaching $1.97. 17,336 shares of the company’s stock were exchanged. Novogen has a 52-week low of $1.72 and a 52-week high of $3.09. The company’s market cap is $33.86 million. The stock has a 50-day moving average price of $1.97 and a 200 day moving average price of $2.09.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/zacks-novogen-ltd-nasdaqnvgn-given-consensus-recommendation-of-strong-buy-by-analysts.html
Novogen Company Profile
Novogen Limited (Novogen) is a drug discovery company. The Company is primarily engaged in pharmaceutical research and development. The Company’s operations include CanTx Inc, its United States-based joint venture company with Yale University. Novogen has two drug technology platforms (the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that have application across a range of degenerative diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novogen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.